Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMNVP8Q)

Drug Name
Tivantinib Drug Info
Synonyms
Tivantinib; 905854-02-6; ARQ-197; ARQ197; ARQ 197; Tivantinib (ARQ 197); (3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; UNII-PJ4H73IL17; PJ4H73IL17; 1000873-98-2; (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; Tivantinib [USAN:INN]; 1228508-24-4; Tivantinib; ARQ197; ARQ 197, Tivantinib; Tivantinib (ARQ-197); ARQ 197 (Tivantinib); cc-86; SCHEMBL44944; Tivantinib (JAN/USAN/INN); GTPL7948; CHEMBL2103882; CHEBI:91398; QCR-102
Cross-matching ID
PubChem CID
11494412
ChEBI ID
CHEMBL91398
CAS Number
CAS 905854-02-6
TTD Drug ID
D0ZI1F

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Proteasome 2.20 0.00e+0 44/46 (95.65%) PSMB7;PSMA7;PSMD12;...
Ribosome biogenesis in eukaryotes 2.12 0.00e+0 52/108 (48.15%) GNL2;RPP40;GAR1;...
Amoebiasis 1.98 7.44e-3 99/102 (97.06%) ACTN1;CXCL8;CXCL3;...
Mineral absorption 1.90 1.12e-2 48/60 (80%) MT1E;MT1H;MT1HL1;...
IL-17 signaling pathway 1.80 1.34e-2 84/94 (89.36%) FOSL1;CXCL8;CXCL3;...
NF-kappa B signaling pathway 1.80 1.30e-2 90/104 (86.54%) CXCL8;RELB;CXCL3;...
Focal adhesion 1.76 2.39e-2 180/201 (89.55%) CAV1;ACTN1;PDGFC;...
Rheumatoid arthritis 1.76 2.09e-2 78/93 (83.87%) CXCL8;CXCL3;CXCL2;...
Chagas disease 1.76 1.86e-2 93/102 (91.18%) CXCL8;TGFB1;SERPINE1;...
Glycine, serine and threonine metabolism -1.70 4.21e-2 31/40 (77.5%) BHMT;ALDH7A1;CTH;...
Fatty acid degradation -1.74 3.41e-2 40/43 (93.02%) ACAT1;ECHS1;ADH7;...
Glycolysis / Gluconeogenesis -1.77 2.64e-2 56/67 (83.58%) GAPDH;GPI;BPGM;...
Metabolism of xenobiotics by cytochrome P450 -1.83 1.32e-2 49/77 (63.64%) CYP1B1;GSTM4;CYP2D6;...
Alanine, aspartate and glutamate metabolism -1.88 8.81e-3 27/37 (72.97%) ASS1;GFPT1;NIT2;...
Citrate cycle (TCA cycle) -1.90 4.40e-3 30/30 (100%) SUCLG2;SDHD;SUCLA2;...
Mismatch repair -1.97 2.94e-3 22/23 (95.65%) MLH1;POLD2;RPA2;...
Glyoxylate and dicarboxylate metabolism -2.00 4.40e-3 23/30 (76.67%) GRHPR;ACAT2;SHMT1;...
DNA replication -2.01 0.00e+0 34/36 (94.44%) RNASEH2A;POLE2;POLD1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone marrow
Neuroblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SH-SY5Y CVCL_0019 Homo sapiens 0.04uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.04uM - 10uM 6H, 24H
SK-BR-3 CVCL_0033 Homo sapiens 0.08uM - 10uM 6H, 24H
Breast carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BT-20 CVCL_0178 Homo sapiens 0.08uM - 10uM 6H, 24H
Hs 578T CVCL_0332 Homo sapiens 0.08uM - 10uM 6H, 24H
Normal (Epithelial)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HME1 CVCL_2950 Homo sapiens 0.04uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.04uM - 10uM 6H, 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Embryonic stem cell
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUES 3 CVCL_B062 Homo sapiens 0.04uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 0.04uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.04uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
A549/Asc-1 CVCL_YA87 Homo sapiens 0.04uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.04uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H
SK-L CVCL_1699 Homo sapiens 0.04uM - 10uM 24H